1. Akira, S. & Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499–511 (2004).
2. Song, D. H. & Lee, J.-O. Sensing of microbial molecular patterns by Toll-like receptors. Immunol. Rev. 250, 216–229 (2012).
3. Yang, L. & Seki, E. Toll-like receptors in liver fibrosis: cellular crosstalk and mechanisms. Front. Physiol. 3, 138 (2012).
4. Alexopoulou, L. et al. Hyporesponsiveness to vaccination with Borrelia burgdorferi OspA in humans and in TLR1- and TLR2-deficient mice. Nat. Med. 8, 878–84 (2002).
5. Takeuchi, O. et al. Discrimination of bacterial lipoproteins by Toll-like recepttor 6. Int. Immunol. 13, 933–940 (2001).
6. Takeuchi, O. et al. Cutting Edge: Role of Toll-Like Receptor 1 in Mediating Immune Response to Microbial Lipoproteins. J. Immunol. 169, 10–14 (2002).
7. Poltorak, A. Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene. Science (80-. ). 282, 2085–2088 (1998).
8. Shimazu, R. et al. MD-2, a Molecule that Confers Lipopolysaccharide Responsiveness on Toll-like Receptor 4. J. Exp. Med. 189, 1777–1782 (1999).
9. Hayashi, F. et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410, 1099–1103 (2001).
10. Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413, 732–738 (2001).
11. Heil, F. et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303, 1526–9 (2004).
12. Diebold, S. S., Kaisho, T., Hemmi, H., Akira, S. & Reis e Sousa, C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303, 1529–31 (2004).
13. Lund, J. M. et al. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. 101, 5598–5603 (2004).
14. Hemmi, H. et al. A Toll-like receptor recognizes bacterial DNA. Nature 408, 740–745 (2000).
15. Bauer, S. et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U. S. A. 98, 9237–42 (2001).
16. Jin, M. S. et al. Crystal Structure of the TLR1-TLR2 Heterodimer Induced by Binding of a Tri-Acylated Lipopeptide. Cell 130, 1071–1082 (2007).
17. Kang, J. Y. et al. Recognition of Lipopeptide Patterns by Toll-like Receptor 2-Toll-like Receptor 6 Heterodimer. Immunity 31, 873–884 (2009).
18. Liu, L. et al. Structural Basis of Toll-Like Receptor 3 Signaling with Double-Stranded RNA. Science (80-. ). 320, 379–381 (2008).
19. Park, B. S. et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex. Nature 458, 1191–1195 (2009).
20. Yoon, S. Il et al. Structural basis of TLR5-flagellin recognition and signaling. Science (80-. ). 335, 859–864 (2012).
21. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805–20 (2010).
22. O’Neill, L. A. J. & Bowie, A. G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7, 353–364 (2007).
23. Hoshino, K. et al. IκB kinase-α is critical for interferon-α production induced by Toll-like receptors 7 and 9. Nature 440, 949–953 (2006).
24. Honda, K. et al. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434, 772 (2005).
25. Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T. & Seya, T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. Nat. Immunol. 4, 161–7 (2003).
26. Yamamoto, M., Sato, S. & Hemmi, H. Role of Adaptor TRIF in the MyD88-Independent Toll-Like Receptor Signaling Pathway. Science (80-. ). 301, 640–643 (2003).
27. Sasai, M. et al. Cutting Edge: NF-κB-activating kinase-associated protein 1 participates in TLR3/Toll-IL-1 homology domain-containing adapter molecule-1-mediated IFN regulatory factor 3 activation. J. Immunol. 174, 27– 30 (2005).
28. Häcker, H. et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature 439, 204–207 (2006).
29. Oganesyan, G. et al. Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 439, 208– 211 (2006).
30. Zhang, Z. et al. Structural Analysis Reveals that Toll-like Receptor 7 Is a Dual Receptor for Guanosine and Single-Stranded RNA. Immunity 45, 737– 748 (2016).
31. Tanji, H. et al. Toll-like receptor 8 senses degradation products of single-stranded RNA. Nat. Struct. Mol. Biol. 22, 109–116 (2015).
32. Ohto, U. et al. Structural basis of CpG and inhibitory DNA recognition by Toll-like receptor 9. Nature 520, 702–705 (2015).
33. Song, W. et al. Structural basis for specific recognition of single-stranded RNA by Toll-like receptor 13. Nat. Struct. Mol. Biol. 22, 782–7 (2015).
34. Roach, J. C. et al. The evolution of vertebrate Toll-like receptors. Proc. Natl. Acad. Sci. U. S. A. 102, 9577–9582 (2005).
35. Ewald, S. E. et al. The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor. Nature 456, 658–62 (2008).
36. Park, B. et al. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat. Immunol. 9, 1407–1414 (2008).
37. Sepulveda, F. E. et al. Critical Role for Asparagine Endopeptidase in Endocytic Toll-like Receptor Signaling in Dendritic Cells. Immunity 31, 737–748 (2009).
38. Hipp, M. M. et al. Processing of human toll-like receptor 7 by furin-like proprotein convertases is required for its accumulation and activity in endosomes. Immunity 39, 711–721 (2013).
39. Ishii, N., Funami, K., Tatematsu, M., Seya, T. & Matsumoto, M. Endosomal Localization of TLR8 Confers Distinctive Proteolytic Processing on Human Myeloid Cells. J. Immunol. 193, 5118–5128 (2014).
40. Renn, C. N. et al. TLR Activation of Langerhans Cell-Like Dendritic Cells Triggers an Antiviral Immune Response. J. Immunol. 177, 298–305 (2006).
41. Zarember, K. A. & Godowski, P. J. Tissue Expression of Human Toll-Like Receptors and Differential Regulation of Toll-Like Receptor mRNAs in Leukocytes in Response to Microbes, Their Products, and Cytokines. J. Immunol. 168, 554–561 (2002).
42. Hornung, V. et al. Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides. J. Immunol. 168, 4531–4537 (2002).
43. Suzuki, N. et al. Severe impairment of interleukin-1 and toll-like receptor signalling in mice lacking IRAK-4. Nature 416, 750–754 (2002).
44. Kobayashi, K. et al. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110, 191–202 (2002).
45. Kawai, T. et al. Interferon-α induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5, 1061– 1068 (2004).
46. Shinohara, M. L. et al. Osteopontin expression is essential for interferon-α production by plasmacytoid dendritic cells. Nat. Immunol. 7, 498–506 (2006).
47. Krieg, A. M. & Vollmer, J. Linking Innate Immunity To Autoimmunity. Immunol. Rev. 220, 251–269 (2007).
48. Leadbetter, E. A. et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416, 603–607 (2002).
49. Vollmer, J. et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202, 1575–1585 (2005).
50. Blasius, A. L. & Beutler, B. Intracellular Toll-like Receptors. Immunity 32, 305–315 (2010).
51. Bird, A. P. CpG islands as gene markers in the vertebrate nucleus. Trends Genet. 3, 342–347 (1987).
52. Burge, C., Campbell, A. M. & Karlin, S. Over- and under-representation of short oligonucleotides in DNA sequences. Proc. Natl. Acad. Sci. U. S. A. 89, 1358–62 (1992).
53. Krieg, A. M. et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546–549 (1995).
54. Ballas, Z. K., Rasmussen, W. L. & Krieg, A. M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol. 157, 1840–5 (1996).
55. Kimura, Y. et al. Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN. J. Biochem. 116, 991–994 (1994).
56. Krieg, A. M. Now I know my CpGs. Trends Microbiol. 9, 249–252 (2001).
57. Lipford, G. B. et al. Immunostimulatory DNA: Sequence-dependent production of potentially harmful or useful cytokines. Eur. J. Immunol. 27, 3420–3426 (1997).
58. Hartmann, G. et al. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells. Eur. J. Immunol. 33, 1633–41 (2003).
59. Vollmer, J. et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34, 251–262 (2004).
60. Samulowitz, U. et al. A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. Oligonucleotides 20, 93–101 (2010).
61. Chan, M. P. et al. DNase II-dependent DNA digestion is required for DNA sensing by TLR9. Nat. Commun. 6, 5853 (2015).
62. Yu, D. et al. Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction. Antimicrob Agents Chemother 52, 4320–4325 (2008).
63. Latz, E. et al. Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat Immunol 8, 772–779 (2007).
64. Pohar, J., Kužnik Krajnik, A., Jerala, R. & Benčina, M. Minimal Sequence Requirements for Oligodeoxyribonucleotides Activating Human TLR9. J. Immunol. 194, 3901–3908 (2015).
65. Pohar, J. et al. Short single-stranded DNA degradation products augment the activation of Toll-like receptor 9. Nat. Commun. 8, 15363 (2017).
66. Yi, A. K., Chang, M., Peckham, D. W., Krieg, A. M. & Ashman, R. F. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J. Immunol. 160, 5898–906 (1998).
67. Sen, G. et al. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity. Cell. Immunol. 232, 64–74 (2004).
68. Hartmann, G. & Krieg, A. M. Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells. J. Immunol. 164, 944–953 (2000).
69. Rankin, R. et al. CpG Motif Identification for Veterinary and Laboratory Species Demonstrates That Sequence Recognition Is Highly Conserved. Antisense Nucleic Acid Drug Dev. 11, 333–340 (2001).
70. Pohar, J. et al. Species-Specific Minimal Sequence Motif for Oligodeoxyribonucleotides Activating Mouse TLR9. J. Immunol. 195, 4396– 4405 (2015).
71. Otwinowski, Z. & Minor, W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276, 307–326 (1997).
72. Kabsch, W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 133–144 (2010).
73. Vagin, A. A. & Teplyakov, A. Molecular replacement with MOLREP. Acta Crystallogr. Sect. D Biol. Crystallogr. 66, 22–25 (2010).
74. Emsley, P. & Cowtan, K. Coot: model-building tools for molecular graphics. Acta Crystallogr. D. Biol. Crystallogr. 60, 2126–32 (2004).
75. Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. Sect. D Biol. Crystallogr. 67, 355–367 (2011).
76. Shimizu, N. et al. Software development for analysis of small-angle x-ray scattering data. AIP Conf. Proc. 1741, (2016).
77. Pohar, J. et al. Selectivity of Human TLR9 for Double CpG Motifs and Implications for the Recognition of Genomic DNA. J. Immunol. 198, 2093– 2104 (2017).
78. HAROSH, I., BINNINGER, D. M., HARRIS, P. V., MEZZINA, M. & BOYD, J. B. Mechanism of action of deoxyribonuclease II from human lymphoblasts. Eur. J. Biochem. 202, 479–484 (1991).